Form 4: Odyssey Health CEO Redmond Granted Stock Options

Sentiment:

SEC Form 4 Filing


Odyssey Health's CEO, J Michael Redmond, was granted stock options to purchase 500,000 shares of common stock on June 28, 2024.

Summary

  • J Michael Redmond, the President and CEO of Odyssey Health, Inc., was granted stock options on June 28, 2024.
  • The options allow Redmond to purchase 500,000 shares of Odyssey Health's common stock at an exercise price of $0.10 per share.
  • The options vest in installments: 100,000 immediately, and then 100,000 on July 31, 2024, October 31, 2024, January 31, 2025, and April 30, 2025.
  • The options expire on June 27, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the CEO's ability to improve the company's performance. However, it doesn't provide any concrete information about the company's current financial health or future prospects.

Positives

  • The granting of stock options to the CEO aligns his interests with those of the shareholders.
  • The vesting schedule incentivizes the CEO to remain with the company for the long term.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock options are a common form of executive compensation used to align management's interests with those of shareholders in the biotechnology industry.

Comparison to Industry Standards

  • Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
  • The size of the grant and the vesting schedule are typical for a company of Odyssey Health's size and stage of development.
  • Comparable companies such as Novavax, Moderna, and BioNTech also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

  • Shareholders may view the stock option grant as a positive sign, aligning the CEO's interests with their own.
  • Employees may see the grant as a sign of confidence in the company's future.

Key Dates

DateDescription
06/28/2024Date of the stock option grant and initial vesting of 100,000 shares.
07/31/2024Vesting date for 100,000 shares.
10/31/2024Vesting date for 100,000 shares.
01/31/2025Vesting date for 100,000 shares.
04/30/2025Vesting date for 100,000 shares.
06/27/2034Expiration date of the stock options.
07/16/2024Date of Form 4 filing.

Keywords

stock options, Odyssey Health, ODYY, CEO, J Michael Redmond, executive compensation, Form 4, insider trading

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.